First Approved Kinase Inhibitor for AML

John E.J. Rasko, Timothy Hughes

Research output: Contribution to journalShort survey

5 Citations (Scopus)

Abstract

Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF. Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.

LanguageEnglish
Number of pages1
JournalCell
Volume171
Issue number5
DOIs
Publication statusPublished - 16 Nov 2017

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Rasko, John E.J. ; Hughes, Timothy. / First Approved Kinase Inhibitor for AML. In: Cell. 2017 ; Vol. 171, No. 5.
@article{0d3a96e9a0e547019d80aa28d434c136,
title = "First Approved Kinase Inhibitor for AML",
abstract = "Activating mutations of FLT3 occur in about 30{\%} of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF. Activating mutations of FLT3 occur in about 30{\%} of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.",
author = "Rasko, {John E.J.} and Timothy Hughes",
year = "2017",
month = "11",
day = "16",
doi = "10.1016/j.cell.2017.11.007",
language = "English",
volume = "171",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",

}

First Approved Kinase Inhibitor for AML. / Rasko, John E.J.; Hughes, Timothy.

In: Cell, Vol. 171, No. 5, 16.11.2017.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - First Approved Kinase Inhibitor for AML

AU - Rasko, John E.J.

AU - Hughes, Timothy

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF. Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.

AB - Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF. Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.

UR - http://www.scopus.com/inward/record.url?scp=85034036509&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.11.007

DO - 10.1016/j.cell.2017.11.007

M3 - Short survey

VL - 171

JO - Cell

T2 - Cell

JF - Cell

SN - 0092-8674

IS - 5

ER -